Navigation Links
TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics

SAN DIEGO, May 18 /PRNewswire/ -- TriLink BioTechnologies, Inc. today announced that it has signed a service agreement with Osmetech Molecular Diagnostics to supply reagents for Osmetech's recently launched eSensor(R) Cystic Fibrosis Carrier Detection (CFCD) System and the eSensor(R) XT-8 System for Warfarin Sensitivity.

As part of the agreement, TriLink is providing Osmetech with custom oligonucleotides, which are required reagents for the eSensor(R) detection systems.

"TriLink provides high quality reagents which have contributed to the excellent performance of our eSensor(R) products in the marketplace to date," said Osmetech Molecular Diagnostics COO, Pankaj Singhal.

"TriLink is proud to work with Osmetech in the advancement of this important science and rapidly developing commercial opportunity," said TriLink CEO, Dr. Richard Hogrefe.

About TriLink

TriLink Biotechnologies, Inc. manufactures custom oligonucleotides, modified nucleoside triphosphates and CleanAmp(TM) PCR products for the diagnostic and OEM markets. In addition, custom chemistry, contract research services and ISO/QSR compliant cGMP production facilities are offered. TriLink's solutions help advance drug discovery and biomedical research. Founded in 1996, TriLink is a privately held firm based in San Diego, California and employs approximately 90 scientists and other professionals. For more information about the firm and products, call 858-546-0004, email, or visit our web site at

About Osmetech

Osmetech is an international diagnostics business operating in Boston and Pasadena in the US to serve the molecular diagnostic market targeting hospitals and reference laboratories. Osmetech has a strong patent portfolio and markets FDA 510(k) cleared first- and second-generation electrochemistry-based array systems, the eSensor(R) 4800 platform and the eSensor(R) XT-8 platform, presently available for Cystic Fibrosis Carrier Detection and Warfarin Sensitivity testing, respectively. The eSensor(R) XT-8 system is designed to support a broad test menu. A cytochrome P450 2C9 genotyping test (RUO) is now available while planned menu expansion includes an extended warfarin panel with the proprietary 4F2 marker, a venous thrombosis panel (Factor II, Factor V Leiden and MTHFR) and a RESPLEX(R) respiratory pathogen assay marketed in collaboration with Qiagen that is capable of detecting Swine Flu. For more information about the company and products, call (800) eSensor (373-6767), email, or visit our web site at

    Judy Le

SOURCE TriLink BioTechnologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. TriLink Launches CleanAmp(TM) dNTPs for Hot Start PCR
2. TriLink Awarded a Phase II Grant for a Second Hot Start PCR Project
3. Feldenkrais(R) Movement Institute Announces Simple Non-Surgical Solutions for Jaw and Facial Pain (TMJ)
4. DSM Announces Yield Boosts of 5-10 Fold With XD(R) Technology for Mammalian Manufacturing Platforms
5. TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
6. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
7. Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
8. AlphaVax Announces Promising Results in Melanoma Studies
9. Tris Pharma Announces Acceptance of Its First Two NDAs
10. Bionovo Announces First Quarter 2009 Highlights and Financial Results
11. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
Post Your Comments:
(Date:11/25/2015)... SYDNEY , Nov. 26, 2015  The total global ... nearly 7% over 2015-2016. Latin America ... Asia , (excluding Japan ), is ... continues to face increased healthcare expenditure. In 2013-2014, ... expenditure declined from 43.5% in 2008-2009 to 41.2% in 2013-2014. ...
(Date:11/25/2015)... Nov. 25, 2015 On Tuesday, November ... bellwether trial against Wright Medical Technology, Inc. for ... Conserve metal-on-metal hip implant device, awarded $11 million ... two week trial and three days of deliberations, ... device was defectively designed and unreasonably dangerous, and ...
(Date:11/25/2015)... 25, 2015  Trovagene, Inc. (NASDAQ: TROV ), ... Chief Executive Officer Antonius Schuh, Ph.D., is scheduled to ... Annual Piper Jaffray Healthcare Conference. th ... Palace Hotel in New York ... Mr. Schuh will be available for one-on-one meetings during ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, senior government and UN ... African Centres of Excellence, and public R&D institutions, civil societies and other partners ... the 5th African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The ...
(Date:11/25/2015)... , ... November 25, 2015 , ... According to an ... robot is being more and more widely heralded as a breakthrough for performing hernia ... method has over traditional laparoscopic surgery is that it can greatly reduce the pain ...
(Date:11/25/2015)... ... 2015 , ... On November 25, 2015, officials of Narconon Arrowhead , ... release of a new cutting edge recovery program that has been 50 years in ... and alcohol-addicted individuals with the purpose to free addicts from the symptoms and negative ...
(Date:11/25/2015)... ... ... On November 23rd 2015 Cozy Products, a division of Bird-X ... Products explains what this means for business moving forward. , The Tri Lite heater ... model: to sell personal heaters that reduce energy consumption, are economical and keep people ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Beddit® has ... Beddit Classic sleep tracking systems. The new app features a more intuitive SleepScoreā„¢ that ... understand how well you slept. The SleepScore is created by a proprietary algorithm. Beddit ...
Breaking Medicine News(10 mins):